《希米科：2025走近东方：日本与韩国如何引领下一阶段临床开发新时代白皮书（英文版）（12页）.pdf》由会员分享，可在线阅读，更多相关《希米科：2025走近东方：日本与韩国如何引领下一阶段临床开发新时代白皮书（英文版）（12页）.pdf（12页珍藏版）》请在三个皮匠报告上搜索。

1、2025 Questex Content Marketing.All rights reserved.All registered trademarks are property of their respective owners.PRESENTED BY:PUBLISHED BY:WHITEPAPERBeyond the West:How Japan and South Korea are Shaping the Next Era of Clinical DevelopmentCONTENTSA new direction for clinical development and comm

2、ercial expansion .3Why Japan?.5Japans regulatory overhaul .8 Why South Korea?.9Conclusion.10References.11Contact.12Beyond the West:How Japan and South Korea are Shaping the Next Era of Clinical Development2MARCH 2025PRESENTED BY:PUBLISHED BY:Once overlooked,Japan and South Korea have become valuable

3、 components of pharmas commercial and clinical strategies.Japan is the third-largest market for pharmaceutical spending and the second-largest Asia-Pacific market.Despite this activity,the countrys growing,aging population faces serious unmet need.1 According to recent data from Japans Pharmaceutica

4、l and Medical Devices Agency(PMDA),as of March 2023,86 medicines that had been approved in Europe and/or the U.S.remained unavailable in Japan.2 To combat this drug lag,Japan recently streamlined its regulatory require-ments.Now that its faster to obtain market approval in Japan,pharma companies are

5、 investing in Japan with fresh eyes,recognizing the untapped market opportunity.The Republic of South Korea(aka South Korea or Korea)has also become an active clinical and commercial market.In addition to robust pharmaceu-tical and biotech industries,the country offers advanced medical research cent

6、ers and relatively quick regulatory approval processes.According to a study conducted by the South Korea National Enterprise for Clinical Trials(KoNECT),Seoul,South Korea,has the highest number of clinical trials of any city globally.18 For all its strengths though,the country also suffers from chro